Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: Comparative immunogenicity of COVID-19 vaccination in pregnant and non-pregnant women: a real-world cohort study

Date Published: 2026-05-15

Abstract:
Pregnant individuals are at increased risk of severe COVID-19-related morbidity and adverse obstetric outcomes, highlighting the importance of effective vaccination. Although COVID-19 vaccine safety during pregnancy is well established, real-world evidence on vaccine-induced humoral immunity remains limited. This study compared neutralizing antibody responses after COVID-19 vaccination in pregnant and non-pregnant women and evaluated the effects of vaccine dose number, platform, and timing during pregnancy. This retrospective cohort study included 171 vaccinated women of reproductive age, comprising 95 pregnant and 76 non-pregnant participants. Neutralizing antibody titers were measured using a surrogate virus neutralization test. Vaccine platforms included mRNA vaccines (BNT162b2, Pfizer–BioNTech), inactivated vaccines (CoronaVac, Sinovac), and a small number of heterologous regimens. Antibody levels were compared using the Mann–Whitney U test. Associations between antibody titers and vaccine dose number, age, gestational age, and trimester were assessed using Spearman correlation analyses and Jonckheere–Terpstra trend tests. Pregnant women had significantly lower neutralizing antibody titers than non-pregnant controls (median 5.62 vs. 16.25?AU/mL; p =?0.008) and were less likely to reach the assay’s upper detection limit (?30?AU/mL: 18.9% vs. 43.4%). Although the categorical distribution of vaccine dose counts was broadly similar between groups ( ? 2 p =?0.098), the mean number of doses was significantly lower among pregnant women (1.93?±?0.72 vs. 2.32?±?1.02; p =?0.011), reflecting differences in cumulative vaccine exposure at higher dose levels. Antibody titers were strongly associated with vaccine dose number overall ( ? =?0.341, p <?0.001) and in both pregnant and non-pregnant women. When stratified by dose category, antibody titers did not differ by pregnancy status. Gestational age and trimester were not independently associated with antibody levels, although the dose–response relationship was strongest in second-trimester vaccination. In unadjusted comparisons, mRNA vaccines were associated with numerically higher titers than inactivated vaccines (median 11.30 vs. 7.72?AU/mL; p =?0.165). mRNA platform was also independently associated with higher titers in multivariable analysis ( ? =?0.721, p =?0.030); this finding should be interpreted cautiously given the small inactivated-vaccine subgroup ( n =?18). COVID-19 vaccination elicits robust neutralizing antibody responses in pregnant women, with overall humoral responsiveness preserved despite quantitative differences in antibody magnitude. Lower antibody levels are predominantly explained by differences in cumulative vaccine exposure rather than pregnancy-related immune impairment, although a residual independent association of pregnancy cannot be fully excluded. Completing recommended vaccine schedules is essential to optimize maternal and neonatal protection.

Introduction:
Pregnant individuals are at increased risk of severe COVID-19-related morbidity and adverse obstetric outcomes, highlighting the importance of effective vaccination. Although COVID-19 vaccine safety during pregnancy is well established, real-world evidence on vaccine-induced humoral immunity remains limited. This study compared neutralizing antibody responses after COVID-19 vaccination in pregnant and non-pregnant women and evaluated the effects of vaccine dose number, platform, and timing during pregnancy.

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile